Emily M. Leproust Sells 1,654 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,654 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total value of $74,264.60. Following the completion of the sale, the chief executive officer now directly owns 673,064 shares of the company’s stock, valued at approximately $30,220,573.60. This represents a 0.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Twist Bioscience Stock Down 2.1 %

Shares of NASDAQ TWST opened at $48.17 on Friday. The business’s 50 day moving average is $45.58 and its two-hundred day moving average is $46.74. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -13.38 and a beta of 1.82.

Analysts Set New Price Targets

A number of analysts have issued reports on TWST shares. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Scotiabank lifted their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.90.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the company. Thrivent Financial for Lutherans purchased a new position in shares of Twist Bioscience in the third quarter valued at approximately $43,992,000. Point72 Asset Management L.P. boosted its position in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after buying an additional 613,057 shares during the period. Fred Alger Management LLC grew its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares in the last quarter. State Street Corp increased its position in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.